Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:MIRM News 19 December 2025

Mirum Pharmaceuticals (MIRM) Stock Jumps on New $68.5M TCGX Financing, Bluejay Deal Momentum, and a Fresh $140 Price Target

Mirum Pharmaceuticals (MIRM) Stock Jumps on New $68.5M TCGX Financing, Bluejay Deal Momentum, and a Fresh $140 Price Target

December 19, 2025 — Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) is in the spotlight today after announcing additional financing tied to its planned Bluejay Therapeutics acquisition and drawing bullish analyst commentary that helped power a sharp move in the stock. As of the latest reported trade on Friday, December 19, 2025, MIRM was trading around $76.71, up about 9.15% from the prior close, after touching an intraday high near $77.19. What’s driving Mirum Pharmaceuticals stock today Two catalysts are dominating the narrative on 19.12.2025: That combination—fresh capital + pipeline-driven upgrade energy—is the kind of fuel that can move a mid-cap biotech
19 December 2025
·

Stock Market Today

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop